FDA Approves Lenalidomide ANDA217554 Submission by Deva Holding AS
The FDA has approved the ANDA217554 submission for Lenalidomide by Deva Holding AS.
Published: July 31, 2026
Updated: July 31, 2026
Author: Humanexa Intelligence
Therapeutic area: Hematology / Multiple Myeloma
Asset: Lenalidomide
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Lenalidomide
Indication
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's approval of a generic version of Lenalidomide by Deva Holding AS significantly alters the competitive landscape in the hematology market. Portfolio teams must evaluate the implications for pricing and market share of existing branded products as competition intensifies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market uptake of the generic and any potential pricing strategies from competitors.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.